Notice Number: NOT-HL-16-337

Key Dates
Release Date: August 19, 2016

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

On May 31, 2016, the NHLBI issued funding Opportunity Announcement PAR-16-301 "Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24)". This Notice announces a correction to information regarding the eligibility of Foreign Institutions.

The following section of the FOA is revised accordingly:

Part 2. Full Text of the Announcement

Section III. Eligibility Information

1. Eligible Applicants

Foreign Institutions

Current Language:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. (Based on NOT-HL-16-330)

Revised Language:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

The following sections of the FOA do not need revision and remain unchanged:
Section IV. Application and Submission Information

2. Content and Form of Application Submission

Foreign Institutions

Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.

Section V. Application Review Information

1. Criteria

Additional Review Considerations

Applications from Foreign Organizations

Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Keary A. Cope, PhD
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0287
Email: [email protected]